Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13920732 | 0.86 | TBK1 (0.37) | ALDH1A1MAPTHPGDNPSR1L3MBTL1 | |
| SCHEMBL745424 | 0.83 | TBK1 (0.39) | LMNAIKBKETBK1SUV39H2SMN1; SMN2 | |
| SCHEMBL12208682 | 0.82 | IKBKE (0.41) | ALDH1A1MAPTHPGDNPSR1L3MBTL1 | |
| SCHEMBL20010985 | 0.82 | HTR2C (0.47) | IKBKETBK1SUV39H2TSHRCHRNB4 | |
| SCHEMBL15945568 | 0.82 | LMNA (0.41) | ALDH1A1MAPTHPGDL3MBTL1KDM4E | |
| SCHEMBL15335810 | 0.82 | HTR2C (0.50) | IKBKETBK1SUV39H2PARP10PARP11 | |
| SCHEMBL8972581 | 0.81 | TBK1 (0.41) | MAPTIKBKETBK1SUV39H2SMN1; SMN2 | |
| SCHEMBL14403246 | 0.81 | TBK1 (0.43) | IKBKETBK1SUV39H2 | |
| SCHEMBL17471329 | 0.79 | IKBKE (0.41) | IKBKETBK1SUV39H2CHRNB4CHRNA3 | |
| SCHEMBL2915518 | 0.79 | SUV39H2 (0.45) | ALDH1A1MAPTHPGDNPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026047575-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2026-03-05 | — | — | WO | disclosed |
| EP-3924058-B1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673431-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-01-01 | — | — | US | disclosed |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-12281073-B2 | Substituted piperidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-04-22 | — | — | US | disclosed |
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | NOVARTIS AG (CH) | 2024-10-29 | — | — | US | disclosed |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024180499-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2024-09-06 | — | — | WO | disclosed |
| EP-3984994-B1 | SUBSTITUTED PIPERIDINE COMPOUND AS OREXIN TYPE 2 AGONIST FOR THE TREATMENT OF NARCOLEPSY | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-03 | — | — | EP | disclosed |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20090302273-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CYCLOHEXANE RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090302273-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CYCLOHEXANE RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090302273-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CYCLOHEXANE RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-12-10 | — | — | US | disclosed |
| US-6057006-A | COMPARATIVELY HIGH CLEARING POINT AND LOW POSITIVE OR NEGATIVE DIELECTRIC ANISOTROPY SUITABLE AS COMPONENTS OF LIQUID-CRYSTALLINE MEDIA, IN PARTICULAR FOR TFT AND STN DISPLAYS. | MERCK PATENT GESELLSCHAFT (DE) | 2000-05-02 | — | — | US | disclosed |
| US-6030940-A | FOR TREATING HUMAN UROKINASE-TYPE PLASMINOGEN ACTIVATOR MEDIATED DISORDERS | CHIRON CORPORATION (US) | 2000-02-29 | — | — | US | disclosed |
| US-5656726-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS | CHIRON CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5536853-A | Opiate receptor ligands | CHIRON CORPORATION (US) | 1996-07-16 | — | — | US | disclosed |
| US-5447916-A | Hypotensive agents | CHIRON CORPORATION (US) | 1995-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | RECQL, NRAS, RAB1A | ALDH1A1 810/4885MAPT 2473/4885HPGD 658/4885 |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, HCN3, FZD7 | ALDH1A1 3844/4885MAPT 568/4885HPGD 4487/4885 |
| US-12281073-B2 | Substituted piperidine compound and use thereof | HCRTR2, HCRTR1, NTSR2 | ALDH1A1 1508/4885MAPT 1035/4885HPGD 2153/4885 |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NPBWR1 | ALDH1A1 2868/4885MAPT 2679/4885HPGD 3538/4885 |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | RECQL, NRAS, RAB1A | ALDH1A1 810/4885MAPT 2473/4885HPGD 658/4885 |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, OXTR | ALDH1A1 2188/4885MAPT 1397/4885HPGD 808/4885 |
| US-20090302273-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CYCLOHEXANE RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | ZYX, PYM1, CPNE4 | ALDH1A1 3021/4885MAPT 3064/4885HPGD 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.